Abstract
BackgroundPostnatal head growth failure is well recognised in very preterm infants (VPI), the largest deficit occurs at 3–4 weeks followed by some catch-up growth until 36weeks corrected gestational age (36wCGA)....
Highlights
Humidified High Flow Nasal Cannula Therapy (HHHFNC) therapy is a modality of non-invasive ventilation which provides humidified, warm, high flow oxygen (>2 litres per minute)
Following the conclusions drawn from this data, a further prospective study aim would be to demonstrate whether HHHFNC has superiority or non-inferiority to Continuous Positive Airway Pressure (CPAP) therapy
Postnatal head growth failure is well recognised in very preterm infants (VPI), the largest deficit occurs at 3–4 weeks followed by some catch-up growth until 36weeks corrected gestational age (36wCGA)
Summary
HHHFNC therapy is a modality of non-invasive ventilation which provides humidified, warm, high flow oxygen (>2 litres per minute). It has been proposed as an alternative to CPAP in maintaining children without the need for intubation and mechanical ventilation. Method A retrospective study analysing records of 27 paediatric patients treated with HHHFNC therapy who presented with bronchiolitis between September 2010 – March 2011. The paired t-test analyses demonstrated statistical significance for changes in values for interval of difference of pH (p value -0.016), respiration rate (p value-0.001) and heart rate (p value -0.00). Following the conclusions drawn from this data, a further prospective study aim would be to demonstrate whether HHHFNC has superiority or non-inferiority to CPAP therapy. Preventing Early Postnatal Head Growth Failure in Very Preterm Infants: The Randomised Controlled SCAMP Nutrition Study doi:10.1136/archdischild-2013-304107.181
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
